KCG
MDGL icon

Knight Capital Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Knight Capital Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$76K Buy
+437
New +$114K ﹤0.01% 2996

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Knight Capital Group's MDGL Position: Q2 2013 in Review

Knight Capital Group opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2013: 437 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2996 among its holdings.

84 funds tracked by Wall St. Rank hold MDGL as of Q2 2013.

  • Knight Capital Group held 437 shares of Madrigal Pharmaceuticals worth $76K as of Q2 2013.
  • Madrigal Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2996 holding.
  • 84 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.